Lilly Official Offers Tips On Reducing Contamination Risks In Cleanrooms
Executive Summary
Having a multilayered approach to sterility assurance is key to preventing contamination in cleanrooms, with equal attention paid to gowning, aseptic technique, engineering technique and proactive and detailed trending, says Eli Lilly official. Official also advises manufacturers to follow both USP Chapter 1116 and the EU’s Annex 1 if they want their sterility assurance programs to pass muster with inspectors and do business globally.
You may also be interested in...
EU Defends Plans To Keep 'PUPSIT' Testing In Revised EU GMP Annex 1
An EU regulatory official is undeterred by pleas from industry to modify a requirement that manufacturers conduct pre-use, post-sterilization integrity testing of filters for sterile drugs under EU GMP Annex 1. The original annex required PUPSIT testing and the revision also is expected to require it. The revised annex has been repeatedly delayed, and now is expected early next year.
Significant Revisions To Annex 1 Cleanroom Standard Soon To Be Released
MHRA inspector and rapporteur Andrew Hopkins anticipates that the long-awaited revision of Annex 1 on environmental monitoring standards for cleanrooms will soon be released and offers a preview of some of the changes.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”